BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Nabriva Therapeutics Presents Extended Phase II Results for Pleuromutilin Antibiotic BC-3781


9/19/2011 10:33:08 AM

Vienna, Austria- 19 September 2011- Nabriva Therapeutics, a biotechnology company focused on developing a new class of antibiotics for serious infections caused by resistant pathogens, today announced that a series of studies including data from the first Phase 2 study will be presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago, Illinois, USA. The studies further support that the Company’s lead product BC-3781, the first of a new class of systemically available pleuromutilin antibiotics, can be used both orally and intravenously for the treatment of bacterial skin and lung infections.

Nabriva’s CMO, Dr. William Prince will be presenting detailed data from the Phase II study in a talk entitled “A Phase 2 Study Comparing the Safety and Efficacy of Two Doses of BC-3781 Versus Vancomycin in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)”. The study was the first to treat patients with a pleuromutilin administered intravenously and results showed that not only did BC-3781 have the same efficacy as Vancomycin, but that it was also safe and well-tolerated. The talk will take place during the session on “New Issues in Managing Skin and Skin Structure Infections (SSTI's)” at 1:30 pm on Sunday, September 18th.

In addition, the posters to be presented will show important PK/PD data from the Phase II study, including an analysis of early time endpoints as suggested in the FDA’s draft guidance and a confirmation of the therapeutic dose of BC-3781, plus data demonstrating the good tissue penetration of BC-3781 and the lack of resistance to BC-3781 world-wide.

Dr. Prince commented: “We are delighted with the quality of this Phase II study and look forward to presenting the excellent data. This is perhaps the most significant Phase II data for some time, given that we have proof-of-concept for the systemic use of a new class of antibiotics in man to treat ABSSSI, community-acquired bacterial pneumonia (CABP) and other indications.”

These studies will be presented at the 51st ICAAC in Chicago, held on September 17- 20th 2011. The titles and contributors to each poster mentioned above are as follows:

Population Pharmacokinetic (PPK) Analyses for BC-3781 Using Phase 2 Data C. M. Rubino, B. Xue, S. M. Bhavnani, W. T. Prince, Z. Ivezic-Schoenfeld, W. W. Wicha, P. G. Ambrose

Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis for Efficacy of BC-3781 Using New Clinical Trial Endpoints in Patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

S. M. Bhavnani, J. P. Hammel, C. M. Rubino, C. C. Bulik, D. K. Reynolds, Z. Ivezic-Schoenfeld, W. W. Wicha, R. Novak, W. T. Prince, P. G. Ambrose

A Phase 2 Study Comparing the Safety and Efficacy of Two Doses of BC-3781 Versus Vancomycin in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

W. T. Prince, F. Obermayr, Z. Ivezic-Schoenfeld, C. Lell, W. W. Wicha, D. B. Strickmann, K. J. Tack, R. Novak

Antimicrobial Activity of BC-3781, an Investigational Pleuromutilin, Tested Against Organisms Isolated From Patients with Community-Acquired Respiratory Tract (CARTI) and Acute Bacterial Skin and Skin Structure (ABSSSI) Infections

H. S. Sader, D. J. Farrell, D. J. Biedenbach, R. N. Jones

The Pharmacokinetics of BC-3781 in Muscle and Adipose Tissue in Healthy Subjects

M. Zeitlinger, F. Obermayr, A. Burian, R. Badreslam, B. Burian, M. Müller, D. Strickmann, R. Novak, W. T. Prince

About Nabriva Therapeutics

Nabriva Therapeutics is a biotechnology company focused on developing a new class of antibiotics for the treatment of serious infections caused by resistant pathogens. Nabriva’s lead systemic product, BC-3781, is being developed for the treatment of serious skin infections and bacterial pneumonia caused by S. aureus, S. pneumoniae, H. influenza, Mycoplasma, Legionella and other bacteria, including drug resistant strains such as MRSA and Vancomycin resistant E. faecium. In addition, Nabriva Therapeutics’ topical pleuromutilin product candidate, BC-7013, is in clinical Phase I. Nabriva Therapeutics has a proven track record in world-class medicinal chemistry, clinical expertise, a seasoned management team and solid IP. Nabriva’s current shareholders include: Phase4 Ventures HBM Partners, The Wellcome Trust, Global Life Science Ventures, Novartis Venture Fund and Sandoz. Nabriva Therapeutics is located in Vienna, Austria.

For more information on Nabriva please visit www.nabriva.com

Contact:

Nabriva Therapeutics AG

Dr. David Chiswell

CEO

T: +43 (0)1 740 93-0

OFFICE@NABRIVA.COM

College Hill Life Sciences

Dr. Robert Mayer

Senior Account Manager

T: +49 (0)89 57001806

robert.mayer@collegehill.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->